| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(1 year, 2 months ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(3 months ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(2 months from now) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(2 years from now) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(3 years from now) | |
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(4 years from now) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(7 years from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(7 years from now) | |
Pradaxa is owned by Boehringer Ingelheim.
Pradaxa contains Dabigatran Etexilate Mesylate.
Pradaxa has a total of 9 drug patents out of which 2 drug patents have expired.
Expired drug patents of Pradaxa are:
- US6087380*PED
- US9925174
Pradaxa was authorised for market use on 19 October, 2010.
Pradaxa is available in capsule;oral dosage forms.
Pradaxa can be used as method of reversing the anticoagulant effect of dabigatran using idarucizumab.
The generics of Pradaxa are possible to be released after 20 July, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Jun 21, 2024 |
| Pediatric Exclusivity (PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 19 October, 2010
Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab
Dosage: CAPSULE;ORAL
PRADAXA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic